Aspartylglucosaminuria (AGU) is a lysosomal storage disexpression of AGA was demonstrated in the liver. The ease leading to mental retardation, which is caused by adenovirus vectors were also injected intraventricularly into deficiency of aspartylglucosaminidase (AGA). AGU is the brain of AGU mice resulting in AGA expression in the strongly enriched in the Finnish population in which one ependymal cells lining the ventricles, and further, diffusion major mutation called AGU Fin has been identified. The molof AGA into the neighbouring neurons. Also, AGA enzyme ecular pathogenesis of AGU as well as the biology of the injected intraventricularly was shown to transfer across the AGA enzyme have been extensively studied, thus giving a ependymal cell layer. One month after administration of the profound basis for therapeutic interventions. In this study wild-type Ad-AGA, a total correction of lysosomal storage we have performed adenovirus-mediated gene transfer to in the liver and a partial correction in brain tissue surroundthe recently produced mouse model of AGU, which exhibits ing the ventricles was observed. After administration of the similar pathophysiology as that in humans. Recombinant Ad-AGU virus the lysosomal storage vacuoles in liver or adenovirus vectors encoding for the human AGA and brain remained unchanged. These data demonstrate that AGU Fin polypeptides were first applied in primary neurons the lysosomal storage in AGU can be biologically corrected of AGU mouse to demonstrate wild-type and mutant AGA and furthermore, in the brain a limited number of expression in vitro. In vivo, both of the adenovirus vectors transduced cells can distribute AGA enzyme to the were injected into the tail vein of AGU mice and the surrounding areas.